PRECISION TOOLS
FOR FUSION DETECTION
With Pairidex, you’ll get the data you need to drive confident, timely decisions.
PRECISION TOOLS
FOR FUSION DETECTION
We’re Transforming how fusion-driven hematological malignancies are detected.
Our CLIA-certified laboratory-based testing service provides the tools needed to make faster, more informed decisions about treatment efficacy and disease monitoring. By combining cutting-edge technology with a commitment to advancing the field, we enable scientists and researchers to make decisions with confidence.
Bespoke Assays
Tailored assays and personalized panels meet the unique demands of your research.
Affordable & Scalable
Advanced testing without the high costs of traditional methods. Cut costs, not corners.
Exceptional Sensitivity
Detect one fusion-bearing cell in 100,000 for unparalleled accuracy.
Rapid Results
Our testing process delivers data in days, not weeks.
The Pairidex Difference
Not all testing methods are created equal—and that’s where Pairidex stands apart. Our approach redefines disease monitoring by addressing the limitations of traditional methods.
Higher Sensitivity
Higher SensitivityDetect what standard techniques like flow cytometry or sequencing might miss, ensuring no crucial details are overlooked.
Reliable Reproducibility
Standardized processes ensure consistent results.
Affordability Without Compromise
Advanced technology at a fraction of the price, so your research dollars go further.
Minimally Invasive
A simple blood draw provides accurate results without the discomfort of a biopsy.
Innovative Approach
Pairidex outperforms traditional methods with reproducible, standardized, and highly sensitive testing. Using just one tube of blood, our proprietary technology delivers a clear positive or negative result. For positive cases, we provide an accurate quantification of fusion abundance, giving researchers a clear assessment of disease burden.
1
Blood sample collection
2
Nucleic acid isolation
3
Fusion detection via droplet digital PCR
4
1
Blood sample collection
2
Nucleic acid
isolation
3
Fusion detection via droplet digital PCR
4
Analysis and
results reporting
The Pairidex Early Detection Window:
Identify Relapse Earlier
Our high-sensitivity assay reveals molecular recurrence well before conventional techniques.
The figure illustrates how more frequent, sensitive testing with Pairidex offers a broader opportunity for early detection—what we call the Pairidex early detection window.
PUBLICATIONS & PRESS
The Journal of Molecular Diagnostics
Droplet Digital PCR for Oncogenic KMT2A Fusion Detection
BioSTL News
Unlocking Potential: How Science Coach and BioSTL Are Shaping the Future of STEM Education
St. Louis Business Journal
Startups to Watch 2025: Local startup wants to make a difference in blood cancer treatment
Connect with us
Discover how our innovative solutions can transform your approach to cancer detection and monitoring. We’d love to show you what we can do.